Stifel raised the firm’s price target on Tandem Diabetes (TNDM) to $20 from $16 and keeps a Hold rating on the shares as part of the firm’s 2026 overview note for the dental, diabetes, and aesthetics sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes coverage transferred with a Buy at TD Cowen
- Tandem Diabetes Care: Multi‑Phase Growth Reacceleration Driven by Patch Pump Launch and Margin Recovery Supports Upgraded $25 Target
- Tandem Diabetes price target raised to $25 from $18 at Bernstein
- Tandem Diabetes price target raised to $25 from $16 at Goldman Sachs
- Tandem Diabetes Care Targets Longer-Wear Infusion Sets in New Home-Use Study